Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-κB Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy.
J Neuromuscul Dis
; 6(1): 43-54, 2019.
Article
en En
| MEDLINE
| ID: mdl-30452422
ABSTRACT
BACKGROUND:
Edasalonexent is an orally administered small molecule designed to inhibit NF-κB, which is activated from infancy in Duchenne muscular dystrophy and is central to causing muscle damage and preventing muscle regeneration.OBJECTIVE:
Evaluate the safety, tolerability, pharmacokinetics and exploratory pharmacodynamics of three doses of edasalonexent in ambulatory males ≥4 to <8 years of age with genetically confirmed Duchenne muscular dystrophy.METHODS:
This was a 1-week, open-label, multiple-dose study with 3 sequential ascending doses (33, 67 and 100âmg/kg/day) of edasalonexent administered under different dietary conditions to 17 males with a mean age of 5.5 years.RESULTS:
All doses of edasalonexent were well tolerated, with no serious adverse events, no drug discontinuations and no dose reductions. The majority of adverse events were mild, and the most common adverse events were gastrointestinal (primarily diarrhea). Edasalonexent was rapidly absorbed with peak levels observed 2-6 hours after dosing and exposures appeared to increase nearly proportionally to dose for the 2 lower and all 3 doses under low-fat and high-fat meal conditions, respectively. Only minor plasma accumulation of edasalonexent was observed with 7 days of dosing. After treatment with edasalonexent for 7 days, levels of NF-κB-regulated genes and serum proteins were decreased.CONCLUSIONS:
This first report of edasalonexent oral administration for one week in male pediatric patients with Duchenne muscular dystrophy showed that treatment was well tolerated and inhibited NF-kB pathways.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Salicilamidas
/
Ácidos Araquidónicos
/
Distrofia Muscular de Duchenne
/
Fármacos Neuromusculares
Límite:
Child
/
Child, preschool
/
Humans
/
Male
Idioma:
En
Revista:
J Neuromuscul Dis
Año:
2019
Tipo del documento:
Article
País de afiliación:
Estados Unidos